Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 242 of 6351
-
New drug ALXN1720 aims to ease muscle weakness in myasthenia gravis
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heated chemotherapy after stomach cancer surgery: a new hope?
Disease control Recruiting nowThe goal of this clinical trial is to learn about Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer after Laparoscopic Gastrectomy with D2 Lymphadenectomy. The main question it aims to answer is: whether HIPEC can effectively improving …
Phase 3 • Sponsor: The Affiliated Hospital of Qingdao University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Can everyday drugs shield the liver from Cirrhosis's worst threats?
Prevention CompletedThe study aims to compare the potential benefit of allopurinol versus atorvastatin in reducing the risk of developing cirrhosis-related complications, delaying the onset of hepatocellular carcinoma, and improving survival. Furthermore, the study aims to evaluate their impact on p…
Phase 2/3 • Sponsor: Tanta University • Aim: Prevention
Last updated Aug 13, 2026 00:00 UTC
-
A single day of online therapy could curb postpartum depression
Prevention CompletedTo conduct a randomized controlled trial (N=408) examining the impact of an online cognitive behavioural therapy (CBT)-based workshop on rates of postpartum depression (i.e., EPDS scores at 2-months postpartum) when added to treatment as usual (TAU) compared to TAU alone.
Sponsor: McMaster University • Aim: Prevention
Last updated Aug 16, 2026 00:00 UTC
-
New hope for hodgkin lymphoma: drug combo aims to boost transplant success
Disease control Recruiting nowThis study is being done to determine if two new drugs can shrink or eliminate classical Hodgkins lymphoma.
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Could a targeted immune blocker tame a deadly heart side effect of cancer drugs?
Disease control CompletedImmune-checkpoint-inhibitors (ICI) have revolutionized treatment for about 20 cancer types. They unleash anti-tumor immune responses. Unfortunately, in 0.36-1.23% of patients, this activation can also lead to lethal immune-related adverse events (irAEs) that can affect any organ.…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Which antipsychotic best tames Parkinson's psychosis? a Head-to-Head trial aims to find out
Disease control Recruiting nowPatients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's m…
Phase 4 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New combo drug shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedResearchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulate…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted immune drug calm rare muscle inflammation?
Disease control CompletedThis study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certa…
Phase 2/3 • Sponsor: argenx • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a smart stimulator restore hand function after spinal cord injury?
Disease control Recruiting nowThe purpose of this study is to assess the efficacy of non-invasive (transcutaneous) closed-loop electrical spinal cord stimulation for recovery of upper limb function (Aim 1) and spasticity (Aim 2) following spinal cord injury.
Sponsor: University of Washington • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Two-Drug cocktail targets Hard-to-Treat cancer mutation
Disease control OngoingThis is a phase 1/2, open label study of D-1553 in combination with IN10018 to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation
Phase 1/2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a drinkable vaccine stop Shigella's grip?
Vaccine CompletedThis is a trial to evaluate the safety, reactogenicity, immunogenicity and efficacy of a 10\^6 cfu dose of an oral live-attenuated S. sonnei vaccine candidate, WRSs2, in up to 120 healthy males and non-pregnant females aged 18-49, inclusive. This is a two-phase study, an outpatie…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Aug 12, 2026 00:00 UTC
-
Can a Low-Dose immune calmer slow Alzheimer's decline?
Disease control OngoingStudy aims at evaluating the therapeutic efficacy and safety of low-dose IL-2 immunomodulatory treatment in patients with early AD, in a phase II, randomized, double blind, placebo-controlled phase II clinical trial. Patients with AD at early stage will be recruited and randomize…
Phase 2 • Sponsor: Centre Hospitalier St Anne • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a drug and heat combo beat a parasitic skin disease?
Disease control CompletedA four (4) -arm randomised control clinical trial to evaluate miltefosine, thermotherapy and the combination miltefosine-thermotherapy are effective, safe and tolerable alternative treatment options to treat cutaneous leishmaniasis caused by L. tropica, in Pakistan compared to th…
Phase 3 • Sponsor: Medecins Sans Frontieres, Netherlands • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can a new drug combo revive Immunotherapy's power against resistant tumors?
Disease control Stopped earlyThis is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or…
Phase 1/2 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New combo attack on leukemia shows promise in early trial
Disease control OngoingAcute lymphoblastic leukemia (ALL) is the most frequent cancer in children, decreases in adolescence and adulthood, and a second peak can be recorded starting from the 6th decade of life. While the outcome in children is excellent, in the adolescent/adult population, the prognosi…
Phase 2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Can a Two-Drug attack outsmart resistant breast cancer?
Disease control Recruiting nowThe aim of this trial is to study the safety, pharmacokinetics and preliminary efficacy of the HER2-targeted antibody-drug conjugate GQ1001 in combination with pyrotinib in patients with HER2-positive metastatic breast cancer patients who had failed previous anti-HER2 treatment.
Phase 1/2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New combo therapy shows promise for saving rectal cancer Patients' anuses
Disease control CompletedAt present, there are no relevant studies or reports on the effect of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter prospective ra…
Phase 2/3 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill aims to ease sickle cell pain and boost hemoglobin
Disease control Recruiting nowThe purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.
Phase 2/3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New radiation treatment shows promise for tough skin cancers
Disease control OngoingThis is a multi-center clinical study enrolling up to 86 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radia…
Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC